ClinicalTrials.gg
RecruitingNCT05663710Updated Nov 3, 2026

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

A Phase 1/2 interventional study of 177Lu girentuximab and Nivolumab in Advanced Cancer and Clear Cell Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by M.D. Anderson Cancer Center · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.
Updated Nov 3, 2026Now RecruitingNow Suspended+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center — 10 open to participants now, 25 under way, 1 of them phase 3. Carcinoma, Renal Cell · M.D. Anderson Cancer Center.

Planned enrollment
10th of 54
100 · median 43
Started
2023
with 3 others
Phase 1/2
6 of 56
1 open now
Primary completion
2027-10
later than 9 of 24 live
Registered
45th of 56
by date

Among the 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center, this one is the 10th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 1/2, reaches primary completion later than 9 of the 24 other live ones, and was the 45th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

Read the detailed description

Primary Objectives:

  • To determine safety of combination 177Lu girentuximab in combination with nivolumab plus cabozantinib in subjects with previously untreated ccRCC.
  • To evaluate CR rate in the combination of 177Lu girentuximab with nivolumab plus cabozantinib in subjects with previously untreated ccRCC. 2. CR rate by RECIST 1.1 by investigator

Secondary Objectives:

  • To evaluate ORR of 177Lu girentuximab in combination with nivolumab plus cabozantinib in subjects with previously untreated ccRCC.
  • To evaluate PFS of 177Lu girentuximab in combination with nivolumab plus cabozantinib in subjects with previously untreated ccRCC.
03

Conditions studied

  • Advanced Cancer
  • Clear Cell Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has the ability to understand and willingness to sign a written ICF before the performance of any study-specific procedures on this protocol and 2022-0515
  2. Age ≥ 18 years
  3. Has locally advanced or RCC with predominantly clear cell subtype
  4. Has at least one as defined by version 1.1
  5. Has an (ECOG) performance status (PS) of 0-1
  6. Has adequate organ function defined as follows:

    a. ≥ 1,500/µL, level ≥ 9 g/dL and count (Plt) i. ≥ 100,000/µL without transfusion or growth factor support within 2 weeks prior to obtaining the hematology values at screening; b. ≥ 40 mL/min/1.73m2 c. Transaminase levels (/ALT) ≤ 3.0 × (ULN); total i. (TBILI) ≤ 1.5 mg/dL in the absence of Gilbert's disease

  7. Women of child beariring potential must have a negative serum preganancy test within 7 days before first study drug administration
  8. Female patients of child bearing potential, or a male patients with a female partner of (defined as all women physiologically capable of becoming pregnant), must agree to use a highly effective method of during screening, during the period of drug administration and for 120 days after stopping study drug administration. Highly effective contraception methods include the following:

    1. Total abstinence (defined as refraining from heterosexual intercourse during the entire period outlined above),
    2. Male or female sterilization, or

    Use of at least one of the following:

    Use of oral, injectable, transdermal, intravaginal, or implantable hormonal methods of contraception i. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation ii. Progestogen-only hormonal contraception associated with inhibition of ovulation c. Placement of an intrauterine device or intrauterine system

  9. Able to swallow oral medications
  10. Able to provide tumor tissue sample (archival or recent acquisition)
  11. Patients with are eligible providing other measurable disease exists and brain lesions are controlled for one month (requiring no therapy) and are not life threatening.

Exclusion criteria

Exclusion Criteria:

  1. Has received treatment with any frontline systemic therapy for RCC
  2. Has a history of or spinal cord compression
  3. Has a history of disease requiring active therapy
  4. Has a history of except:

    1. Patients may be enrolled if they have treated brain metastases with no evidence of progression or hemorrhage after therapy for brain metastases (e.g. radiation therapy, surgery, radiosurgery) AND
    2. Patients may be enrolled if they do not require ongoing treatment with dexamethasone or anti-epileptic drugs
  5. Has had radiation therapy for bone metastases within 2 weeks, or any other external radiation therapy (5 days or longer) to sites other than bone, within 4 weeks before administration of the first dose of study treatment. Patients with ongoing major complications from prior radiation therapy are not eligible.
  6. Has uncontrolled or poorly controlled hypertension, as defined by a sustained blood pressure (BP) > 140/90 with or without antihypertensive treatment
  7. Has had any major cardiovascular event within 6 months prior to study drug administration including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, , pulmonary embolism, clinically significant ventricular arrhythmias (e.g. sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or Class III or IV heart failure
  8. Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results, in the opinion of the investigator or medical monitor
  9. Has an active infection requiring systemic treatment
  10. Is participating in another therapeutic clinical trial
  11. Is receiving chronic concomitant treatment with strong inducers or CYP3A4 inhibitors
  12. Has manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease
  13. Has GI disorders including those associated with a high risk of perforation or fistula formation:

    1. Tumors invading the GI-tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction
    2. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before administration of the first dose of study treatment. Note: complete healing of an intra-abdominal abscess must be confirmed before administration of the first dose of study treatment
  14. Has tumor invading or encasing any major blood vessels
  15. Has other clinically significant disorders such as:

    1. Serious non-healing wound/ulcer/bone fracture
    2. Moderate to severe hepatic impairment ( B or C).
    3. Requirement for hemodialysis or peritoneal dialysis
    4. History of solid organ transplantation
  16. Has had major surgery (e.g., GI surgery, removal or of brain metastasis) within 2 months before the first study drug administration. Complete wound healing from major surgery must have occurred 1 month before the first study drug administration and from minor surgery (e.g., simple excision, tooth extraction) at least 10 days before the first study drug administration. Patients with clinically relevant ongoing complications from prior surgery are not eligible
  17. Has a prior or concomitant invasive other than RCC with the exception of adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma in situ or any other malignancy from which the patient has remained disease free for more than 2 years.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (Biopsy)

    Participants within 2 weeks of starting the first dose of 177Lu-girentuximab

    Drug: 177Lu girentuximab · Drug: Nivolumab · Drug: Cabozantinib · Drug: ArabinoFuranosylGuanine [18F]F-AraG

  • Experimental
    Cohort 2 (Biopsy)

    Participants within 2 weeks of Cycle 4

    Drug: 177Lu girentuximab · Drug: Nivolumab · Drug: Cabozantinib · Drug: ArabinoFuranosylGuanine [18F]F-AraG

  • Experimental
    Cohort 3 (Biopsy)

    Participants at the time of progression or at 20 months post treatment

    Drug: 177Lu girentuximab · Drug: Nivolumab · Drug: Cabozantinib · Drug: ArabinoFuranosylGuanine [18F]F-AraG

Interventions

  • Drug177Lu girentuximab

    Given by IV (vein)

  • Given by IV (vein)

    Also known as: BMS-936558, Opdivo

  • Given by PO

    Also known as: XL-184, XL184

  • DrugArabinoFuranosylGuanine [18F]F-AraG

    Given by IV (vein)

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Oct 2027, 52 months after the start.

Of 41 non-industry phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 132. This study's planned 52 months is below that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Dec 23, 2022
StartActual
Jun 30, 2023
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended→Recruiting Reason for stopping removed
changed Oct 8, 2026 · changed Nov 3, 2026
Sites
MD Anderson Cancer Center is now Recruiting
Nov 3, 2026
Contact
Study contact now listed: added e•••@mdanderson.org · •••7232. See the current contact
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • MD Anderson Cancer Center · Houston, United StatesContact added e•••@mdanderson.org · •••7232Contact added (no phone or email listed)
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    MD Anderson Cancer Center is now Recruiting
    Contact Study contact now listed: added e•••@mdanderson.org · •••7232. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • MD Anderson Cancer Center · Houston, United StatesContact added e•••@mdanderson.org · •••7232Contact added (no phone or email listed)
  2. Oct 8, 2026
    Recruiting→Suspended
    Why stopped PI requested
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05663710
Collaborators
Telix Pharmaceuticals (Innovations) Pty Limited, United States Department of Defense
Responsible party
Sponsor
First posted
Dec 23, 2022
Start date
Jun 30, 2023
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Eric Jonasch, MD
Contact
ejonasch@mdanderson.org
(713) 563-7232
Eric Jonasch, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion